Revance Therapeutics | RVNC - Operating Expenses

Revance Therapeutics reported $194.33M in Operating Expenses for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Operating Expenses Change
Abbvie ABBV:US USD 9.62B 590M
ALKERMES ALKS:US USD 325.26M 12.26M
Bristol Myers Squibb BMY:US USD 9.46B 716M
Cara Therapeutics CARA:US USD 34.57M 90K
Coherus Biosciences CHRS:US USD 96.84M 29.03M
Eli Lilly And LLY:US USD 5.47B 200.3M
Endo International Ordinary Shares ENDP:US USD 1.18B 1.13B
Horizon Pharma HZNP:US USD 768.1M 3.34M
JAZZ PHA JAZZ:US USD 1.24B 319.62M
Johnson & Johnson JNJ:US USD 19.51B 1.54B
Merk MRK:US USD 10.32B 624M
Neurocrine Biosciences NBIX:US USD 308.6M 8.5M
Pacira Pharmaceuticals PCRX:US USD 181.85M 35.67M
Procter & Gamble PG:US USD 15.99B 315M
Revance Therapeutics RVNC:US USD 194.33M 87.83M
Supernus Pharmaceuticals SUPN:US USD 132.99M 45.88M
Teva Pharmaceutical Industries TEVA:US USD 4.74B 1.56B